Myeloma: Classification and risk assessment

Seminars in Oncology

Volumn 40, Issue 5, 2013, Pages 554-566

  Fonseca, Rafael ^a   Monge, Jorge ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CHROMOSOME 17; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC ANALYSIS; GENOMIC INSTABILITY; HEREDITY; HUMAN; HYPERDIPLOID MYELOMA; LIGHT CHAIN; MYELOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; SMOLDERING MYELOMA; SURVIVAL; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CYTOGENETICS; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; RISK ASSESSMENT; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84886891720     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.07.002     Document Type: Article

References (113)

1. S.V. Rajkumar, and R.A. Kyle Multiple myeloma: diagnosis and treatment Mayo Clin Proc 80 2005 1371 1382
2. S.V. Rajkumar, M.Q. Lacy, and R.A. Kyle Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma Blood Rev 21 2007 255 265
3. O. Landgren, R.A. Kyle, and R.M. Pfeiffer Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 113 2009 5412 5417
4. B.M. Weiss, J. Abadie, P. Verma, R.S. Howard, and W.M. Kuehl A monoclonal gammopathy precedes multiple myeloma in most patients Blood 113 2009 5418 5422
5. P.L. Bergsagel, W.M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma Blood 106 2005 296 303
6. C. Debes-Marun, G. Dewald, and S. Bryant Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma Leukemia 17 2003 427 436
7. N.V. Smadja, D. Leroux, and J. Soulier Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases Genes Chromosomes Cancer 38 2003 234 239
8. R. Fonseca, C.S. Debes-Marun, and E.B. Picken The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma Blood 102 2003 2562 2567
9. A. Rio-Machin, B.I. Ferreira, and T. Henry Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype Leukemia 27 2013 925 931
10. W.J. Chng, S. Kumar, and S. Vanwier Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling Cancer Res 67 2007 2982 2989
11. R.A. Kyle, T.M. Therneau, S.V. Rajkumar, D.R. Larson, M.F. Plevak, and L.J. Melton 3rd Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later Mayo Clin Proc 79 2004 859 866
12. J. Ackermann, P. Meidlinger, and N. Zojer Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undedetermined significance Br J Haematol 103 1998 1161 1163
13. H. Kaufmann, J. Ackermann, and C. Baldia Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma Leukemia 18 2004 1879 1882
14. R. Konigsberg, J. Ackermann, and H. Kaufmann Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance Leukemia 14 2000 1975 1979
15. W.J. Chng, S.A. Van Wier, and G.J. Ahmann A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS Blood 106 2005 2156 2161
16. R. Fonseca, R.J. Bailey, and G.J. Ahmann Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood 100 2002 1417 1424
17. R.A. Kyle, E.D. Remstein, and T.M. Therneau Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma N Engl J Med 356 2007 2582 2590
18. K.M. Dhodapkar, S. Barbuto, and P. Matthews Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma Blood 112 2008 2878 2885
19. M.V. Dhodapkar Myeloid neighborhood in myeloma: cancer's underbelly? Am J Hematol 84 2009 395 396
20. T. Rasmussen, M. Kuehl, M. Lodahl, H.E. Johnsen, and I.M. Dahl Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition some plasma cell tumors Blood 105 2005 317 323
21. W.J. Chng, N. Gonzalez-Paz, and T. Price-Troska Clinical and biological significance of RAS mutations in multiple myeloma Leukemia 22 2008 2280 2284
22. D. Billadeau, D.F. Jelinek, N. Shah, T.W. LeBien, and B. Van Ness Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6 Cancer Res 55 1995 3640 3646
23. O. Landgren, G. Gridley, and I. Turesson Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States Blood 107 2006 904 906
24. O. Landgren, J.A. Katzmann, and A.W. Hsing Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana Mayo Clin Proc 82 2007 1468 1473
25. O. Landgren, and B.M. Weiss Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis Leukemia 23 2009 1691 1697
26. A. Baker, E. Braggio, and S. Jacobus Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach Blood 121 2013 3147 3152
27. A.J. Greenberg, C.M. Vachon, and S.V. Rajkumar Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites Leukemia 26 2012 609 614
28. B.M. Weiss, A. Minter, and J. Abadie Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients Am J Hematol 86 2011 475 478
29. M. Brousseau, X. Leleu, and J. Gerard Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients Clin Cancer Res 13 2007 6026 6031
30. L. Agnelli, S. Fabris, and S. Bicciato Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma Br J Haematol 136 2007 565 573
31. M.C. Trendle, P.R. Greipp, and T. Leong Prognostic significance of the S-phase fraction of light chain restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma (meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1996 15
32. G.W. Dewald, R.A. Kyle, G.A. Hicks, and P.R. Greipp The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis Blood 66 1985 380 390
33. R. Fonseca, E. Blood, and M. Rue Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood 101 2003 4569 4575
34. J.J. Keats, T. Reiman, and C.A. Maxwell In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression Blood 101 2003 1520 1529
35. H. Avet-Loiseau, T. Facon, and B. Grosbois Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation Blood 99 2002 2185 2191
36. H. Avet-Loiseau, M. Attal, and P. Moreau Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood 109 2007 3489 3495
37. H. Chang, S. Sloan, and D. Li The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant Br J Haematol 125 2004 64 68
38. M. Pineda-Roman, M. Zangari, and F. van Rhee VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma Leukemia 22 2008 1419 1427
39. J.D. Shaughnessy Jr., F. Zhan, and B.E. Burington A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Blood 109 2007 2276 2284
40. H. Avet-Loiseau, B.G. Durie, and M. Cavo Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project Leukemia 27 2013 711 717
41. R. Fonseca, D. Harrington, and M.M. Oken Prognostic significance of 13q- deletions and the t(11;14)(q13;q32) in myeloma (MM); an interphase FISH Study of 351 patients entered into the Eastern Cooperative Oncology Group E9487 clinical trial Blood 96 2000 547a
42. K. Nishida, M. Taniwaki, S. Misawa, and T. Abe Nonrandom rearrangement of chromosome 14 at band q32.33 in human lymphoid malignancies with mature B-cell phenotype Cancer Res 49 1989 1275 1281
43. M. Chesi, P.L. Bergsagel, L.A. Brents, C.M. Smith, D.S. Gerhard, and W.M. Kuehl Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines Blood 88 1996 674 681
44. H. Avet-Loiseau, T. Facon, and A. Daviet 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma Intergroupe Francophone du Myelome. Cancer Res 59 1999 4546 4550
45. F. Zhan, Y. Huang, and S. Colla The molecular classification of multiple myeloma Blood 108 2006 2020 2028
46. R.E. Tiedemann, N. Gonzalez-Paz, and R.A. Kyle Genetic aberrations and survival in plasma cell leukemia Leukemia 22 2008 1044 1052
47. S.R. Hayman, R.J. Bailey, and S.M. Jalal Translocations involving heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis Blood 98 2001 2266 2268
48. Harrison C, Mazullo H, Cheung K, et al. Chromosomal abnormalities in systemic amyloidosis. In: Proceedings of the VIII International Myeloma Workshop. 2001; Banff, Alberta, Canada; 2001:P18.
49. M. Chesi, E. Nardini, and L.A. Brents Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 Nature Genet 16 1997 260 264
50. M. Chesi, P.L. Bergsagel, and O.O. Shonukan Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma Blood 91 1998 4457 4463
51. H. Avet-Loiseau, X. Leleu, and M. Roussel Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) J Clin Oncol 28 2010 4630 4634
52. H. Avet-Loiseau, F. Malard, and L. Campion Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 117 2011 2009 2011
53. R. Fonseca, P.L. Bergsagel, and J. Drach International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 23 2009 2210 2221
54. W. Xiong, X. Wu, and S. Starnes An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma Blood 112 2008 4235 4246
55. J. Drach, J. Ackermann, and E. Fritz Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy Blood 92 1998 802 809
56. J.J. Keats, R. Fonseca, and M. Chesi Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma Cancer Cell 12 2007 131 144
57. D.R. Carrasco, G. Tonon, and Y. Huang High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients Cancer Cell 9 2006 313 325
58. W.J. Chng, T. Price-Troska, and N. Gonzalez-Paz Clinical significance of TP53 mutation in myeloma Leukemia 21 2007 582 584
59. H. Chang, C. Qi, Q.L. Yi, D. Reece, and A.K. Stewart p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation Blood 105 2005 358 360
60. I. Hanamura, J.P. Stewart, and Y. Huang Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation Blood 108 2006 1724 1732
61. R. Fonseca, S.A. Van Wier, and W.J. Chng Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma Leukemia 20 2006 2034 2040
62. M.A. Chapman, M.S. Lawrence, and J.J. Keats Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
63. W.J. Chng, G.F. Huang, and T.H. Chung Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma Leukemia 25 2011 1026 1035
64. A. Gabrea, M.L. Martelli, and Y. Qi Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors Genes Chromosomes Cancer 47 2008 573 590
65. H. Avet-Loiseau, F. Gerson, F. Magrangeas, S. Minvielle, J.L. Harousseau, and R. Bataille Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors Blood 98 2001 3082 3086
66. N.V. Smadja, C. Bastard, C. Brigaudeau, D. Leroux, and C. Fruchart Hypodiploidy is a major prognostic factor in multiple myeloma Blood 98 2001 2229 2238
67. B. Barlogie, R. Alexanian, D. Dixon, L. Smith, L. Smallwood, and K. Delasalle Prognostic implications of tumor cell DNA and RNA content in multiple myeloma Blood 66 1985 338 341
68. M.J. Calasanz, J.C. Cigudosa, and M.D. Odero Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma Br J Haematol 98 1997 418 425
69. A.B. Fassas, T. Spencer, and J. Sawyer Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma Br J Haematol 118 2002 1041 1047
70. R.J. Morgan Jr., N.J. Gonchoroff, J.A. Katzmann, T.E. Witzig, R.A. Kyle, and P.R. Greipp Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma Am J Hematol 30 1989 195 200
71. S. Van Wier, E. Braggio, and A. Baker Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma Haematologica 2013 Epub ahead of print
72. W.J. Chng, E. Braggio, and G. Mulligan The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition Blood 111 2008 1603 1609
73. O. Decaux, L. Lode, and F. Magrangeas Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome J Clin Oncol 26 2008 4798 4805
74. A. Anguiano, S.A. Tuchman, and C. Acharya Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma J Clin Oncol 27 2009 4197 4203
75. A. Broyl, D. Hose, and H. Lokhorst Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients Blood 116 2010 2543 2553
76. G. Mulligan, C. Mitsiades, and B. Bryant Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib Blood 109 2007 3177 3188
77. B. Nair, F. van Rhee, and J.D. Shaughnessy Jr. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial. 2006-66 with VRD maintenance Blood 115 2010 4168 4173
78. J. Shi, G.J. Tricot, and T.K. Garg Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma Blood 111 2008 1309 1317
79. R. Kuiper, A. Broyl, and Y. de Knegt A gene expression signature for high-risk multiple myeloma Leukemia 26 2012 2406 2413
80. H. Avet-Loiseau, C. Li, and F. Magrangeas Prognostic significance of copy-number alterations in multiple myeloma J Clin Oncol 27 2009 4585 4590
81. V. Hucthagowder, R. Meyer, and C. Mullins Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma Cancer Genet 205 2012 474 478
82. J.J. Keats, M. Chesi, and J.B. Egan Clonal competition with alternating dominance in multiple myeloma Blood 120 2012 1067 1076
83. B.A. Walker, C.P. Wardell, and L. Melchor Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma Blood 120 2012 1077 1086
84. G.J. Morgan, B.A. Walker, and F.E. Davies The genetic architecture of multiple myeloma Nat Rev Cancer 12 2012 335 348
85. T.-H. Chung, G. Mulligan, R. Fonseca, and W.-J. Chng A novel measure of chromosome instability can account for prognostic difference in multiple myeloma PLoS One 8 2013 e66361
86. A. Broyl, R. Kuiper, and M. van Duin High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance Blood 121 2013 624 627
87. J.B. Egan, K.M. Kortuem, and A. Kurdoglu Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease Br J Haematol 161 2013 748 751
88. P. Sonneveld, I.G. Schmidt-Wolf, and B. van der Holt Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial J Clin Oncol 30 2012 2946 2955
89. K. Neben, H.M. Lokhorst, and A. Jauch Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p Blood 119 2012 940 948
90. M. Cavo, L. Pantani, and M.T. Petrucci Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma Blood 120 2012 9 19
91. J.F. San Miguel, R. Schlag, and N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 2008 906 917
92. M.V. Mateos, A. Oriol, and J. Martinez-Lopez Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial Blood 120 2012 2581 2588
93. L. Rosinol, A. Oriol, and A.I. Teruel Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Blood 120 2012 1589 1596
94. A.K. Stewart, P.L. Bergsagel, and P.R. Greipp A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy Leukemia 21 2007 529 534
95. J. Haessler, J.D. Shaughnessy Jr., and F. Zhan Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling Clin Cancer Res 13 2007 7073 7079
96. M.A. Gertz, M.Q. Lacy, and A. Dispenzieri Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood 106 2005 2837 2840
97. A.J. Jakubowiak, D. Dytfeld, and K.A. Griffith A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma Blood 120 2012 1801 1809
98. C.B. Reeder, D.E. Reece, and V. Kukreti Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial Leukemia 23 2009 1337 1341
99. P.G. Richardson, E. Weller, and S. Lonial Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 2010 679 686
100. M. Attal, V. Lauwers-Cances, and G. Marit Lenalidomide maintenance after stem-cell transplantation for multiple myeloma N Engl J Med 366 2012 1782 1791
101. P.L. McCarthy, K. Owzar, and C.C. Hofmeister Lenalidomide after stem-cell transplantation for multiple myeloma N Engl J Med 366 2012 1770 1781
102. A. Palumbo, O. Sezer, and R. Kyle International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation Leukemia 23 2009 1716 1730
103. M.A. Dimopoulos, M. Delforge, and R. Hajek Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial Haematologica 98 2013 784 788
104. P. Falco, F. Cavallo, and A. Larocca Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients Leukemia 27 2013 695 701
105. G.J. Morgan, W.M. Gregory, and F.E. Davies The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis Blood 119 2012 7 15
106. B. Paiva, M.B. Vidriales, and J. Cervero Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Blood 112 2008 4017 4023
107. B. Paiva, M.B. Vidriales, and J.J. Perez Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients Haematologica 94 2009 1599 1602
108. B. Paiva, M.B. Vidriales, and G. Mateo The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients Blood 114 2009 4369 4372
109. B. Paiva, N.C. Gutierrez, and L. Rosinol High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma Blood 119 2012 687 691
110. B. Paiva, M.B. Vidriales, and L. Rosinol A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly-diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control Leukemia 2013 [Epub ahead of print]
111. M. Ladetto, G. Pagliano, and S. Ferrero Correlation between clinical outcome and disease kinetics by quantitative PCR in myeloma patients following post-transplant consolidation with bortezomib, thalidomide and dexamethasone Blood (ASH Annual Meeting Abstracts) 114 2009 960
112. M. Ladetto, G. Pagliano, and S. Ferrero Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma J Clin Oncol 28 2010 2077 2084
113. M. Cavo, P. Tacchetti, and F. Patriarca Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 2010 2075 2085